Iberdomide in Combination with Dex and Dara, Bort, or Cfz in Pts with RRMM

Iberdomide in Combination with Dexamethasone (Dex) and Daratumumab (Dara), Bortezomib (Bort), Or Carfilzomib (Cfz) In Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) In this video: IBER is an oral, novel cereblon E3 ligase modulator (CELMoD) compound with marked synergistic tumoricidal and immune-stimulatory effects in combination with proteasome inhibitors (PIs) or anti-CD38 monoclonal antibodies, preclinically and clinically. CC-220-MM-001 (NCT02773030) is an ongoing phase 1/2 study evaluating the maximum tolerated dose, recommended phase 2 dose (RP2D), safety, and preliminary efficacy of IBER with different treatment combinations in independent cohorts, in pts with RRMM. In this video: Dr. Sagar Lonial (Winship Cancer Institute, Atlanta, Georgia, USA) discusses the results of Iberdomide in combination with dexamethasone and daratummab, bortezomib, or carfilzomib in relpased refractory multiple myeloma. Conclusions: In heavily pretreated pts with RRMM, IberDd, IberVd, and IberKd showed a manageable safety profile and promising efficacy including CRs, even among DARA- and BORT-refractory pts. The study is ongoing. These results support further development of IBER-based regimens in MM, including the initiation of phase 3 combination studies. _______________ Improving Lives Through Research and Patient Care In the United States, an estimated 32,270 new multiple myeloma cases will be diagnosed in 2021. 159,985 new myeloma cases are diagnosed yearly. Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy. Subscribe to our channel: Visit our website at: Find us online: Facebook: @myeloma | Twitter: @IMFMyeloma | Instagram: @imfmyeloma | LinkedIn: Support the IMF! Category Nonprofits & Activism License Standard YouTube License